Clinical Trial

IASO-782 in Autoimmune Hematological Diseases

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with autoimmune hematological diseases. The study is designed to assess the safety and tolerability of IASO-782 for the treatment of autoimmune haematological diseases (ITP and wAIHA).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-30.
Status change: Not Yet Recruiting → Recruiting 2026-05-26
Trial Details
NCT Number NCT06534021
Lead Sponsor Shanghai IASO Biotechnology Co., Ltd
Conditions Autoimmune Thrombocytopenia, Warm Autoimmune Haemolytic Anaemia
Enrollment 16 participants
Start Date 2024-08-08
Primary Completion 2027-10-09 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-29